$0.53
+0.01(1.92%)
Mkt Cap $1M
$0.35
$11.10
52-Week Range
At A Glance
1
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
2
Most recently: . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February (2026-03-03).
$1M
Market Cap
—
Revenue
-$5M
Net Income
Employees1
Fundamentals
How The Business Makes Money
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001022899
ISINUS74365N3017
CUSIP74365N301
Phone212 994 8200
Address149 Fifth Avenue, New York City, NY, 10010, US
SEC EDGAR